1
|
Goodwin R, Jonker D, Chen E, Kennecke H, Cabanero M, Tsao MS, Vickers M, Bohemier C, Lim H, Ritter H, Tu D, Seymour L. A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. Invest New Drugs 2019; 38:1077-1084. [PMID: 31506897 DOI: 10.1007/s10637-019-00814-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Accepted: 06/07/2019] [Indexed: 11/29/2022]
Abstract
Background Resistance to Epidermal Growth Factor inhibition (EGFRi) in patients with KRAS wild-type (wt) Colorectal Cancer (CRC) may occur as a result of PI3K/AKT/mTOR signaling. We conducted a study to establish the recommended phase II dose (RP2D) and response rate of panitumumab, an EGFRi, plus BKM120, a PI3K inhibitor, in advanced CRC. Methods Patients with chemotherapy refractory KRAS wt CRC, who were EGFRi naive were enrolled. A 3 + 3 dose escalation design was utilized. The starting dose of panitumumab was 6 mg/kg iv every 2 weeks with BKM120 at 60 mg oral daily. Results Nineteen patients were treated and 17 were evaluable for response. The starting dose was not tolerable (mucositis, fatigue). At dose level (DL) 1, three of six patients discontinued treatment due to toxicity, DL - 1 had no significant toxicity. Panitumumab 6 mg/kg iv q 2 weeks with BKM120 60 mg given 5 out of 7 days per week was declared the RP2D. One patient (5.9%) who was PTEN and PIK3CA negative by IHC had a partial response, seven had stable disease, and nine had disease progression. Conclusion Panitumumab (6 mg/kg iv q 2 weeks) with BKM120 60 mg given 5 out of 7 days per week was declared the RP2D. Toxicities including fatigue, rash and mucositis. There was little evidence of activity in this biomarker unselected cohort.
Collapse
Affiliation(s)
- Rachel Goodwin
- Ottawa Hospital Research Institute, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, K1H 8L6, Canada.
| | - Derek Jonker
- Ottawa Hospital Research Institute, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, K1H 8L6, Canada
| | - Eric Chen
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | | | - Michael Cabanero
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | - Ming-Sound Tsao
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | - Michael Vickers
- Ottawa Hospital Research Institute, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, K1H 8L6, Canada
| | - Caryn Bohemier
- Ottawa Hospital Research Institute, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, K1H 8L6, Canada
| | - Howard Lim
- BCCA-Vancouver Centre, Vancouver, BC, Canada
| | - Heather Ritter
- Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada
| | - Dongsheng Tu
- Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada
| | - Lesley Seymour
- Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada
| |
Collapse
|
2
|
Jonker DJ, Maroun JA, Auer RAC, Yarom N, Marginean C, Shabana W, Pantarotto JR, Asmis TR, Boushey RP, Goodwin RA, Kendal W, Tadros S, Grimard LJ, Moloo H, Friedlich M, Bohemier C, Marginean H. Phase II study of neoadjuvant irinotecan, capecitabine, oxaliplatin (IXO) followed by chemoradiotherapy (CRT) using concurrent capecitabine for resectable locally advanced rectal cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e14571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Nirit Yarom
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | | | - Wael Shabana
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | | | | | | | | | - Wayne Kendal
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | - Shaheer Tadros
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | | | - Husein Moloo
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | | | - Caryn Bohemier
- The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | | |
Collapse
|